The present invention provides a method of reducing uric acid in a subject in need thereof, comprising administering to the subject a composition comprising an effective amount of fucoxanthin, wherein the fucoxanthin has the effect of reducing uric acid and preventing gout.

The invention concerns a composition made from at least one sulphated polysaccharide, in particular from an algae, and combined with at least one food ingredient. This composition can be used, in particular, in the field of food or in the treatment or prevention of an infection caused by microsporidia in humans or animals. It has useful properties as an antiparasitic agent in humans or animals; for the treatment or prevention of an infection caused by at least one microsporidia in humans or animals; in particular for the treatment or prevention of an infection caused in bees by the microsporidia Nosema, preferably Nosema ceranae or Nosema apis, or indeed for stimulating the immune defences of bees.

The invention concerns a composition made from at least one sulphated polysaccharide, in particular from an algae, and combined with at least one food ingredient. This composition can be used, in particular, in the field of food or in the treatment or prevention of an infection caused by microsporidia in humans or animals. It has useful properties as an antiparasitic agent in humans or animals; for the treatment or prevention of an infection caused by at least one microsporidia in humans or animals; in particular for the treatment or prevention of an infection caused in bees by the microsporidia Nosema, preferably Nosema ceranae or Nosema apis, or indeed for stimulating the immune defences of bees.

The invention concerns a synthetic infant formula composition with a low content of medium-chain fatty acids in specific proportions and a relatively high content of unsaturated fatty acids, preferably polyunsaturated fatty acids. This composition is for infants, preferably preterm infants. This composition has been designed to promote the healthy establishment of cognitive function.

The invention concerns a synthetic infant formula composition with a low content of medium-chain fatty acids in specific proportions and a relatively high content of unsaturated fatty acids, preferably polyunsaturated fatty acids. This composition is for infants, preferably preterm infants. This composition has been designed to promote the healthy establishment of cognitive function.

The present inventive concept relates to a pharmaceutical composition for prevention or treatment of fibrosis or a health functional food composition for prevention or alleviation of fibrosis, each composition containing a 1H-pyrazole-3-amide-based compound or a pharmaceutically acceptable salt thereof as an active ingredient. The compound exhibits a fibrosis mitigation effect in fibrosis-induced mouse models, and thus the compositions containing the compound as an active ingredient can be favorably utilized for prevention or treatment of fibrosis.

The present invention relates to a detoxifying composition containing a new green extract, which is a medicinal herb, as an active ingredient. Thus, toxicities in the human body can be efficiently removed without side effects by activating an enzyme necessary for detoxification.

The present invention relates to a detoxifying composition containing a new green extract, which is a medicinal herb, as an active ingredient. Thus, toxicities in the human body can be efficiently removed without side effects by activating an enzyme necessary for detoxification.

Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements.

Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements.